Day: March 28, 2024

SINGAPORE, March 29, 2024 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for blockchain and high-performance computing, today announced its financial results for the year ended December 31, 2023. Full Year 2023 Financial HighlightsTotal revenue was US$368.6 million, compared to US$333.3 million in 2022. Net loss was US$56.7 million, compared to US$60.4 million in 2022. Adjusted profit was US$22.0 million, compared to US$30.3 million in 2022. Adjusted EBITDA was US$100.3 million, compared to US$93.2 million in 2022. Cash and cash equivalents were US$144.7 million as of December 31, 2023.Linghui Kong, Chief Business Officer of Bitdeer, commented, “We continued to successfully execute on our operational strategies during 2023, as we mined 3,694 Bitcoins,...

Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET  CELEBRATION, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the fourth quarter and year ended December 31, 2023.  “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra. “As we look to 2024, our strategic priorities are clear; first, successfully launch OLPRUVA® and ensure access for patients; second, prepare for the launch of arimoclomol;...

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024 Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumorsBOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We are laser focused on executing the PRESent...

BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — NaaS Technology Inc. (“NaaS” or the “Company”) (Nasdaq: NAAS), the first U.S. listed EV charging service company in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Financial Highlights:Revenues increased by 119% year over year and reached RMB64.4 million (US$9.1 million) for the fourth quarter of 2023. Revenues for the full year of 2023 were RMB320.1 million (US$45.1 million), increasing by 245% year over year. Gross margin was 26.0% for the fourth quarter of 2023, compared with 24.4% for the same period of 2022. Gross margin increased from 6.6% for the full year of 2022 to 27.7% for the full year of 2023. Gross profit grew 2.3 times year over year to RMB16.7 million (US$2.4 million)...

Sixth Consecutive Quarter of YoY Operating Expense and Profitability Improvements Execution of Optimization Initiatives Leads to Material Improvement in FY 2023 Operating Loss and Modified EBITDA NORWALK, Conn., March 28, 2024 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three and twelve months ended December 31, 2023. Q4 2023 Financial Highlights (vs. Q4 2022):Net sales were $11.7 million compared to $15.0 million. Gross profit was $0.5 million compared to $3.4 million, with gross margin of 4.0% compared to 22.9%. Adjusted gross profit, which excludes non-cash inventory adjustments and a one-time change to policy for discounts, increased 26% to $4.3 million with gross margin...

– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the year ended December 31, 2023, and provided a business update. “The last several months have been extremely productive for Unicycive as we advanced both of our clinical development programs and secured new funding from several leading healthcare institutional investors,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive....

Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter and year ended December 31, 2023. “Forian finished the year by executing against our quarterly plan and closed what was a transformational year,” stated Max Wygod, Chairman and Chief Executive Officer of Forian. “In 2023, we successfully completed a major divestiture and refocused our business on healthcare and life sciences, continued revenue growth and achieved Adjusted EBITDA ahead of schedule.” Fourth Quarter 2023 Financial Results Forian delivered the following results for the fourth quarter of 2023:                 Three...

Full-year sales increased 11% to $1.57 billion Fiscal 2023 GAAP EPS of $3.82 impacted by noncash impairment charges of $5.32 per share. Adjusted EPS of $10.15, within guidance range Initiates fiscal 2024 guidance of revenues of $1.630 billion to $1.670 billion, GAAP EPS of $8.80 to $9.20 and adjusted EPS of $9.30 to $9.70ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2023 ended February 3, 2024. Consolidated net sales for the full 53-week fiscal 2023 year increased 11% to $1.57 billion compared to $1.41 billion in the 52-week fiscal 2022 year. Earnings per share (EPS) on a GAAP basis decreased 63% to $3.82 compared to $10.19 in fiscal 2022. Fiscal 2023 results include noncash impairment charges totaling $114 million,...

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant...